Ketamine induces multiple individually distinct whole-brain functional connectivity signatures
This single-blind placebo-controlled study (n=40) investigated the neural and behavioral effects of acute ketamine in healthy participants. Results revealed robust inter-individual variability in both neural and behavioral responses to ketamine, with data-driven individual symptom variation mapping onto distinct neural gradients. These findings emphasize the need to consider individual variation in response to ketamine and suggest potential implications for developing precise pharmacological biomarkers in psychiatry.
Authors
- Erich Seifritz
- Franz Vollenweider
- Katrin Preller
Published
Abstract
Background
Ketamine has emerged as one of the most promising therapies for treatment-resistant depression. However, inter-individual variability in response to ketamine is still not well understood and it is unclear how ketamine’s molecular mechanisms connect to its neural and behavioral effects.
Methods
We conducted a single-blind placebo-controlled study, with participants blinded to their treatment condition. 40 healthy participants received acute ketamine (initial bolus 0.23 mg/kg, continuous infusion 0.58 mg/kg/hr). We quantified resting-state functional connectivity via data-driven global brain connectivity and related it to individual ketamine-induced symptom variation and cortical gene expression targets.
Results
We found that: (i) both the neural and behavioral effects of acute ketamine are multi-dimensional, reflecting robust inter-individual variability; (ii) ketamine’s data-driven principal neural gradient effect matched somatostatin (SST) and parvalbumin (PVALB) cortical gene expression patterns in humans, while the mean effect did not; and (iii) behavioral data-driven individual symptom variation mapped onto distinct neural gradients of ketamine, which were resolvable at the single-subject level.
Conclusions
These results highlight the importance of considering individual behavioral and neural variation in response to ketamine. They also have implications for the development of individually precise pharmacological biomarkers for treatment selection in psychiatry.
Research Summary of 'Ketamine induces multiple individually distinct whole-brain functional connectivity signatures'
Introduction
Earlier whole-brain studies indicate that ketamine produces robust, brain-wide alterations in functional connectivity, including increased global brain connectivity (GBC) in prefrontal cortex and shifts from cortical- to subcortically-centred states. However, those group-average approaches can obscure meaningful inter-individual differences, and prior findings have been inconsistent across timepoints and samples. The authors note that data-driven multivariate methods such as principal component analysis (PCA) can reveal both group-level and individual-level axes of variation and therefore are well suited to test whether ketamine's effects are uni-dimensional (a single uniform pattern) or multi-dimensional (multiple distinct patterns across individuals).
Expert Research Summaries
Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.
Full Text PDF
Full Paper PDF
Pro members can view the original manuscript directly in the browser.
Study Details
- Study Typeindividual
- Journal
- Compounds
- Topics
- Authors
- APA Citation
Moujaes, F., Ji, J. L., Rahmati, M., Burt, J. B., Schleifer, C., Adkinson, B. D., Savic, A., Santamauro, N., Tamayo, Z., Diehl, C., Kolobaric, A., Flynn, M., Rieser, N., Fonteneau, C., Camarro, T., Xu, J., Cho, Y., Repovs, G., Fineberg, S. K., . . . Anticevic, A. (2024). Ketamine induces multiple individually distinct whole-brain functional connectivity signatures. eLife, 13. https://doi.org/10.7554/eLife.84173
References (21)
Papers cited by this study that are also in Blossom
Abdallah, C. G., Averill, L. A., Collins, K. A. et al. · Neuropsychopharmacology (2016)
Bennett, J. N., Blough, M. D., Mitchell, I. et al. · MedRvix (2023)
Berman, R. M., Cappiello, A., Anand, A. et al. · Biological Psychiatry (2000)
Carhart-Harris, R. L., Bolstridge, M., Rucker, J. et al. · Lancet Psychiatry (2016)
De Gregorio, D., Posa, L., Ochoa-Sanchez, R. et al. · Pharmacological Research (2016)
Gasser, P., Holstein, D., Michel, Y. et al. · Journal of Nervous and Mental Disease (2014)
Grimm, O., Gass, N., Weber-Fahr, W. et al. · Psychopharmacology (2015)
Halberstadt, A. L., Geyer, M. A. · Neuropharmacology (2011)
Höflich, A., Hahn, A., Küblböck, M. et al. · International Journal of Neuropsychopharmacology (2015)
Holze, F., Ley, L., Müller, F. et al. · Neuropsychopharmacology (2022)
Show all 21 referencesShow fewer
Joules, R., Doyle, &. O. M., Schwarz, A. J. et al. · Psychopharmacology (2015)
Abdallah, C. G., Charney, D. S., Duman, R. S. et al. · Neuron (2019)
Mueller, F., Musso, F., London, M. et al. · NeuroImage (2018)
Murrough, J. W., Iosifescu, D. V., Chang, L. C. et al. · American Journal of Psychiatry (2013)
Passie, T., Halpern, J. H., Stichtenoth, D. O. et al. · CNS Neuroscience and Therapeutics (2008)
Pokorny, T., Preller, K. H., Kraehenmann, R. et al. · European Neuropsychopharmacology (2016)
Preller, K. H., Herdener, M., Pokorny, T. et al. · Current Biology (2017)
Preller, K. H., Burt, J. B., Adkinson, B. et al. · eLife (2018)
Preller, K. H., Burt, J. B., Adkinson, B. et al. · Biological Psychiatry (2020)
Riva-Posse, P., Reiff, C. M., Edwards, J. A. et al. · Journal of Affective Disorders (2018)
Vollenweider, F. X., Vollenweider-Scherpenhuyzen, M. F. I., Bäbler, A. et al. · NeuroReport (1998)
Cited By (1)
Papers in Blossom that reference this study
Mallevays, M., Fuet, L., Danon, M. et al. · MedRvix (2026)
Your Personal Research Library
Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.